Summer Sessions 5: Dr. Christopher Anzalone Takes RNAi Beyond The Liver

We love to hear from our listeners. Send us a message. Arrowhead Pharma CEO Christopher Anzalone, Ph.D. gives us the inside story on the stake his company claimed on the now re-burgeoning RNAi space, the indications his company is targeting beyond liver disease, and how it's addressing the development and process challenges that must be overcome to further progress RNAi beyond the liver.Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab ...